X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.globenewswire.com/news-release/2024/03/20/2849321/0/en/Achieve-Life-Sciences-Announces-Data-from-Cytisinicline-ORCA-Program-to-be-Presented-at-the-2024-Society-for-Research-on-Nicotine-and-Tobacco-SRNT-Annual-Meeting.html
https://www.globenewswire.com//news-release/2022/12/21/2577829/0/en/Achieve-Life-Sciences-Announces-Patent-Granted-by-USPTO-for-New-Cytisinicline-Formulation.html
https://www.globenewswire.com/news-release/2022/11/14/2555473/0/en/Achieve-Reports-Financial-Results-for-Third-Quarter-2022-and-Provides-Corporate-Update.html#:~:text=Total%20net%20loss%20for%20the,shares%20of%20common%20stock%20outstanding.&text=Achieve%20will%20host%20a%20conference,Monday%2C%20November%2014%2C%202022.
https://www.globenewswire.com/news-release/2022/11/08/2550882/0/en/Achieve-Announces-Early-Completion-of-Target-Enrollment-in-Cytisinicline-e-Cigarette-Cessation-Trial.html
https://www.globenewswire.com/news-release/2022/09/27/2523266/0/en/Achieve-Announces-Completion-of-Target-Enrollment-in-the-Phase-3-ORCA-3-Trial-of-Cytisinicline-for-Smoking-Cessation.html
https://www.globenewswire.com/news-release/2022/06/29/2471234/0/en/Achieve-Life-Sciences-Announces-Initiation-of-Phase-2-ORCA-V1-Clinical-Trial-Evaluating-Cytisinicline-for-Nicotine-e-cigarette-Cessation.html
https://www.globenewswire.com/news-release/2022/06/01/2454205/0/en/Achieve-Life-Sciences-Awarded-Grant-from-the-National-Institutes-of-Health-to-Conduct-Phase-2-Trial-of-Cytisinicline-in-Nicotine-e-cigarette-Users.html
https://www.trialsitenews.com/a/achieve-life-sciences-awarded-grant-from-nih-to-conduct-phase-2-trial-of-cytisinicline-in-nicotine-e-cigarette-users-86e10973
https://www.globenewswire.com/news-release/2022/02/03/2378466/0/en/Achieve-Life-Sciences-Announces-Expansion-of-Cytisinicline-Clinical-Operations-Team-and-Granting-of-Inducement-Award.html
https://www.globenewswire.com/news-release/2022/01/25/2372490/0/en/Achieve-Life-Sciences-Announces-Initiation-of-the-Phase-3-ORCA-3-Clinical-Trial-Evaluating-Cytisinicline-for-Smoking-Cessation.html
https://www.globenewswire.com/news-release/2022/01/04/2360826/0/en/Achieve-Life-Sciences-Announces-Completion-of-Last-Subject-Last-Follow-Up-Visit-in-Phase-3-ORCA-2-Trial-of-Cytisinicline-for-Smoking-Cessation.html
https://www.globenewswire.com/news-release/2021/11/22/2339008/0/en/Achieve-Life-Sciences-Announces-Phase-3-ORCA-2-Trial-of-Cytisinicline-in-Smoking-Cessation-Clears-Final-Review-by-Data-Safety-Monitoring-Committee-DSMC.html
https://finance.yahoo.com/news/achieve-life-sciences-announces-presentation-093000016.html
https://achievelifesciences.com/2021/08/11/achieve-announces-two-patents-granted-by-uspto-for-novel-cytisinicline-dosing-and-administration-regimen/
https://www.medicalbag.com/home/news/for-smoking-cessation-cytisine-not-noninferior-to-varenicline-but-is-better-tolerated/
https://www.biospace.com/article/releases/achieve-announces-completion-of-target-enrollment-of-750-subjects-in-phase-3-orca-2-smoking-cessation-trial-of-cytisinicline/
https://www.prnewswire.com/news-releases/lilly-reveals-critical-barriers-to-optimal-migraine-care-and-insights-from-novel-clinical-and-patient-centric-real-world-evidence-supporting-lillys-preventive-and-acute-treatment-portfolio-at-ahs-2021-301304727.html
https://www.biospace.com/article/releases/achieve-announces-publication-of-the-orca-1-phase-2b-clinical-trial-of-cytisinicline-in-adult-smokers-in-nicotine-and-tobacco-research/
https://www.biospace.com/article/releases/achieve-announces-publication-of-the-rauora-head-to-head-non-inferiority-clinical-trial-comparing-cytisinicline-and-chantix-r-varenicline-in-addiction/#:~:text=The%20published%20results%20indicate%20that,of%20cytisinicline%20when%20compared%20to
https://www.prnewswire.com/news-releases/achieve-life-sciences-announces-start-of-phase-3-orca-2-clinical-trial-evaluating-cytisinicline-for-smoking-cessation-301147315.html
https://www.biospace.com/article/releases/achieve-life-sciences-announces-results-from-evaluation-of-cytisinicline-cytisine-versus-chantix-varenicline-in-5-ht3-receptor-binding-assay-study/
https://www.prnewswire.com/news-releases/achieve-announces-patent-granted-in-the-us-for-novel-analogs-of-cytisinicline-for-use-in-cns-and-addiction-indications-301103740.html
https://www.prnewswire.com/news-releases/achieve-announces-successful-results-from-the-investigator-initiated-rauora-head-to-head-non-inferiority-clinical-trial-comparing-cytisinicline-and-chantix-varenicline-as-a-treatment-to-quit-smoking-301084753.html
https://www.prnewswire.com/news-releases/achieve-receives-4-2-million-from-exercise-of-warrants-300860297.html
Market Place
Share 
